Stifel Financial Corp grew its stake in shares of Hutchison China MediTech Limited (NASDAQ:HCM) by 2.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 36,645 shares of the company’s stock after buying an additional 853 shares during the period. Stifel Financial Corp’s holdings in Hutchison China MediTech were worth $1,174,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Comerica Bank boosted its position in Hutchison China MediTech by 5.1% during the 4th quarter. Comerica Bank now owns 9,069 shares of the company’s stock worth $310,000 after purchasing an additional 439 shares during the period. Aviva PLC boosted its position in Hutchison China MediTech by 3.0% during the 4th quarter. Aviva PLC now owns 23,800 shares of the company’s stock worth $762,000 after purchasing an additional 700 shares during the period. Penserra Capital Management LLC boosted its position in Hutchison China MediTech by 182.3% during the 4th quarter. Penserra Capital Management LLC now owns 1,180 shares of the company’s stock worth $37,000 after purchasing an additional 762 shares during the period. US Bancorp DE boosted its position in Hutchison China MediTech by 650.0% during the 3rd quarter. US Bancorp DE now owns 1,305 shares of the company’s stock worth $42,000 after purchasing an additional 1,131 shares during the period. Finally, Credit Suisse AG boosted its position in Hutchison China MediTech by 0.9% during the 4th quarter. Credit Suisse AG now owns 229,380 shares of the company’s stock worth $7,345,000 after purchasing an additional 2,059 shares during the period. 33.45% of the stock is owned by institutional investors.

A number of brokerages recently weighed in on HCM. Zacks Investment Research cut shares of Hutchison China MediTech from a “hold” rating to a “sell” rating in a research report on Tuesday, March 9th. Mizuho initiated coverage on shares of Hutchison China MediTech in a research report on Tuesday, February 16th. They issued a “buy” rating for the company.

Shares of Hutchison China MediTech stock opened at $28.51 on Thursday. The firm has a market cap of $4.15 billion, a PE ratio of -35.64 and a beta of 1.12. The firm’s 50-day simple moving average is $29.35 and its 200-day simple moving average is $31.35. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.01 and a current ratio of 3.14. Hutchison China MediTech Limited has a 1 year low of $17.69 and a 1 year high of $37.00.

Hutchison China MediTech Company Profile

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It offers research and development services; and manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products.

Further Reading: Understanding Market Liquidity

Institutional Ownership by Quarter for Hutchison China MediTech (NASDAQ:HCM)

Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.